Analytical Data
-
基因名
VP30
- Application
-
别名
(Minor nucleoprotein VP30)
-
种属
strain Musoke-80
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P35258
-
表达区间
1-281aa
-
分子量
39.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VP30 is a key protein in the lifecycle of Ebola virus (EBOV), a member of the Filoviridae family and responsible for severe hemorrhagic fever in humans and other primates. The study of VP30 is crucial for understanding the mechanisms of Ebola virus pathogenesis and immune evasion. VP30 is known to play a significant role in the transcriptional activity of the viral genome, functioning as a transcription factor that is essential for the production of viral mRNA. Research indicates that VP30 can influence the formation of viral nucleoprotein complexes and regulate the viral life cycle, making it a potential target for therapeutic intervention. Given the lack of approved vaccines and treatments for Ebola, elucidating the structure and function of VP30 can provide insights into viral replication processes and highlight strategies for antiviral drug development. Furthermore, studies on VP30 can enhance our understanding of other emerging viral threats and contribute to global health security by identifying novel approaches for vaccine design and therapeutic strategies against filoviruses. As the global community faces the challenge of responding to viral outbreaks, thorough investigations into the functional dynamics of VP30 not only advance virology but also pave the way for innovative solutions to combat future infectious disease emergencies. Overall, research on VP30 is integral to developing effective countermeasures against Ebola virus and mitigating its impact on public health.
